These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9707354)

  • 1. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls.
    Deroubaix X; Lins RL; Lens S; Allemon A; Jeanbaptiste B; Poli G; Acerbi D; Stockis A; Ventura P
    Int J Clin Pharmacol Ther; 1998 Jul; 36(7):386-91. PubMed ID: 9707354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tolerability of a new manidipine and delapril fixed oral combination in young and elderly subjects.
    Stockis A; De Bruyn S; Gengler C; Goethals F; Lens S; Poli G; Acerbi D
    Arzneimittelforschung; 2003; 53(8):554-61. PubMed ID: 13677245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single oral dose pharmacokinetic interaction study of manidipine and delapril in healthy volunteers.
    Stockis A; Gengler C; Goethals F; Jeanbaptiste B; Lens S; Poli G; Acerbi D
    Arzneimittelforschung; 2003; 53(9):627-34. PubMed ID: 14558436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function.
    Valles J; Artigas R; Bertolotti M; Crea A; Muller F; Paredes I; Capriati A
    Methods Find Exp Clin Pharmacol; 2006 Jun; 28 Suppl A():29-36. PubMed ID: 16801990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
    Migoya EM; Stevens CH; Bergman AJ; Luo WL; Lasseter KC; Dilzer SC; Davies MJ; Wagner JA; Herman GA
    Can J Clin Pharmacol; 2009; 16(1):e165-70. PubMed ID: 19221403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of sirolimus (rapamycin) in subjects with severe hepatic impairment.
    Zimmerman JJ; Patat A; Parks V; Moirand R; Matschke K
    J Clin Pharmacol; 2008 Mar; 48(3):285-92. PubMed ID: 18218785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
    Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
    Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
    Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
    Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
    Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
    J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
    Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
    Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination and pharmacokinetics of manidipine in human plasma by HPLC/ESIMS.
    Jing J; Ren W; Chen X; He H; Zhou W; Zhu X; Sun Y; Wang G
    Biomed Chromatogr; 2007 Aug; 21(8):836-40. PubMed ID: 17428020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
    Brockmöller J; Thomsen T; Wittstock M; Coupez R; Lochs H; Roots I
    Clin Pharmacol Ther; 2005 Jun; 77(6):529-41. PubMed ID: 15961984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
    Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
    J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
    Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
    Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of nelfinavir in subjects with hepatic impairment.
    Damle B; Hewlett D; Hsyu PH; Becker M; Petersen A
    J Clin Pharmacol; 2006 Nov; 46(11):1241-9. PubMed ID: 17050789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status.
    Zapater P; Lasso de la Vega MC; Horga JF; Such J; Frances R; Esteban A; Palazòn JM; Carnicer F; Pascual S; Pérez-Mateo M
    Aliment Pharmacol Ther; 2004 Jul; 20(1):29-36. PubMed ID: 15225168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
    Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
    Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
    Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ
    J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.